Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123350 · ClinicalTrials.gov registry record
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
A clinical trial of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07123350 is a study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD) that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 120 participants, below the 758-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07123350, a study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.
Conditions Studied
Interventions
- DRUG Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07123350
The ClinicalTrials.gov registry entry for NCT07123350 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 758-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (84% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 1 intervention - of which Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care is the first listed.
NCT07123350 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07123350 about?
NCT07123350 is a clinical study titled "Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease". The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, ...
What is the current status of trial NCT07123350?
This trial is currently active not recruiting. The enrollment target is 120 participants. The study started on 2025-10-16. Estimated completion is 2026-03-31.
What conditions does trial NCT07123350 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD).
What interventions are being tested in trial NCT07123350?
The interventions under investigation include: Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care (DRUG).
Who is sponsoring clinical trial NCT07123350?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123350 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RECRUITING · Phase 1
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.